Day after day Chinese researchers turn out excellent research using shrna. It can only be a matter of time before numerous clinical trials of shrna begin in that country.
In this latest paper the researchers apply the technology to NSCLC. They don't target the same gene/protein as our program but never-the-less they still show that shrna in vivo is a potent treatment for NSCLC.
The abstract concludes,
"Moreover, the specific downregulation of NUPR1 arrested cells in G0 phase of cell cycle and increased apoptosis rate. Silencing of NUPR1 also suppressed tumor growth by tail vein injection of lentivirus encoded shRNA against NUPR1 in vivo. Our findings revealed that the NUPR1 gene represents a promising target for gene silencing therapy in nonsmall cell lung cancer."
One way or another ddrnai will conquer lung cancer.
